Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947436 | 1.00 | KMT2A (0.40) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL6947439 | 1.00 | KMT2A (0.40) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL4566815 | 0.85 | EPHX2 (0.38) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL4566814 | 0.85 | EPHX2 (0.38) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL5627058 | 0.83 | KDM1A (0.39) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL5627055 | 0.83 | KDM1A (0.39) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL5627065 | 0.83 | KDM1A (0.39) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL5627069 | 0.83 | KDM1A (0.39) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL14441187 | 0.83 | KDM1A (0.39) | KMT2AL3MBTL1CCR5KDM1AMAOB | |
| SCHEMBL2183100 | 0.83 | KDM1A (0.41) | KMT2AL3MBTL1CCR5KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0995744-B1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-13 | — | — | US | claimed |
| EP-0995744-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | claimed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-6656952-B2 | As antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| EP-0995744-B1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0995744-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072608-A1 | CIS-SUBSTITUTED FLUOROMETHYLPYRROLIDINE DERIVATIVE | Q6ZSR9, MRPL21, ABCC1 | KMT2A 1525/4885L3MBTL1 322/4885CCR5 1269/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | KMT2A 3178/4885L3MBTL1 1350/4885CCR5 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.